- Current report filing (8-K)
March 31 2011 - 4:39PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 30, 2011
WELLTEK INCORPORATED
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Nevada
|
|
333-157360
|
|
98-0610431
|
|
|
|
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
1030 North Orange Avenue, Ste. 300,
Orlando, FL
|
|
32801
|
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(407) 704-8950
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 2.01. COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.
Effective on March 30, 2011 (the Closing Date), pursuant to a Stock Purchase Agreement dated
March 30, 2001 (the Stock Purchase Agreement), WellTek Incorporated (WellTek or the Company)
acquired 100% of the issued and outstanding common stock of Stem Cells for Hope, Inc. in exchange
for 15,000,000 of the Companys issued and outstanding common stock. As of the Closing Date,
Vladimir Kravchenko was appointed to the Board of Directors of WellTek and will serve as President
of the Company and Peter Sidorenko will serve as Senior Vice President of the Company.
ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES.
As disclosed under Item 2.01 above, in connection with the Stock Purchase we issued 15,000,000
shares of our common stock to the shareholders of Stem Cells for Hope, Inc.. The securities were
issued in reliance on Rule 506 of Regulation D promulgated under Section 4(2) of the Securities
Act. The issued securities are restricted, and the certificates representing the shares contain a
standard restrictive legend.
|
|
|
ITEM 5.02.
|
|
DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS
|
As a result of the Stock Purchase, on March 30, 2011, the following officers and directors
were appointed:
|
|
|
Name
|
|
Position
|
|
|
|
Vladimir Kravchenko
|
|
President and Director
|
Peter Sidorenko
|
|
Senior Vice President
|
The disclosures in ITEM 2.01 regarding the foregoing appointments and resignations are hereby
incorporated by reference into this ITEM 5.02.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(a) Financial Statements
(i) The applicable financial statement and pro forma financial statement shall be filed within
71 days of the date this initial filing is required to be filed.
(b) Exhibits
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
10.1
|
|
|
Stock Purchase Agreement, dated March 30, 2011
|
|
|
|
|
|
|
10.2
|
|
|
Employment Agreement with Vladimir Kravchenko, dated March 30, 2011
|
|
|
|
|
|
|
10.3
|
|
|
Employment Agreement with Peter Sidorenko, dated March 30, 2011
|
SIGNATURE
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the
registrant has duly caused this
Form 8-k
to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
|
|
|
|
Dated: March 31, 2011
|
WELLTEK INCORPORATED
|
|
|
By:
|
/s/ Mark Szporka
|
|
|
|
Mark Szporka
|
|
|
|
Chief Financial Officer
|
|
|
WellTek (CE) (USOTC:WTKN)
Historical Stock Chart
From Jul 2024 to Aug 2024
WellTek (CE) (USOTC:WTKN)
Historical Stock Chart
From Aug 2023 to Aug 2024